Want to see AVBP full AI Analyst Report?
Top Page
ArriVent BioPharma, Inc.
(NASDAQ:AVBP)
Select Model
Select Model
Rating:51Neutral
Price Target:
$30.00
▼(-3.66% Downside)
Action:Reiterated
Date:08/17/26
The score is driven mainly by financial fundamentals: a strong, low-debt balance sheet helps, but it is offset by a pre-revenue model, widening losses, and sustained cash burn. Technical indicators add downside pressure due to weak momentum and price trading below key moving averages. Valuation is constrained by negative earnings, while corporate events provide a modest positive offset through partnering progress and stable governance.
Positive Factors
Low Leverage and Expanding Asset Base
Minimal debt reduces fixed financial obligations and preserves flexibility to fund clinical development. The substantial increase in assets indicates strong capitalization, providing a more durable base for advancing the pipeline despite current operating losses.
Negative Factors
No Commercial Revenue
The company has not yet demonstrated a revenue-generating commercial model, leaving future funding dependent on successful clinical development, partnerships or eventual product approval. This makes long-term financial progress highly contingent on pipeline execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage and Expanding Asset Base
Minimal debt reduces fixed financial obligations and preserves flexibility to fund clinical development. The substantial increase in assets indicates strong capitalization, providing a more durable base for advancing the pipeline despite current operating losses.
Read all positive factors
ArriVent BioPharma, Inc. (AVBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.54B
Dividend YieldN/A
Average Volume (3M)599.47K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue GrowthN/A
EPS Growth8.22%
CountryUS
Employees77
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.68
Shares Outstanding49,307,728
10 Day Avg. Volume525,635
30 Day Avg. Volume599,470
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.67Price Target Upside43.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.21
Revenue Forecast (FY)N/A
ArriVent BioPharma, Inc. Business Overview & Revenue Model
Company Description
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is ...
How the Company Makes Money
null...
ArriVent BioPharma, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -163.74M | -166.31M | -80.49M | -69.33M | 0.00 | -51.61M |
| Net Income | -163.74M | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Balance Sheet | ||||||
| Total Assets | 394.72M | 333.17M | 274.94M | 163.10M | 182.83M | 43.04M |
| Cash, Cash Equivalents and Short-Term Investments | 373.12M | 312.82M | 218.86M | 150.39M | 163.37M | 37.28M |
| Total Debt | 351.00K | 14.00K | 176.00K | 317.00K | 139.00K | 0.00 |
| Total Liabilities | 27.88M | 25.95M | 17.29M | 11.80M | 8.37M | 1.82M |
| Stockholders Equity | 366.84M | 307.22M | 257.65M | 151.30M | 174.46M | 41.22M |
Cash Flow | ||||||
| Free Cash Flow | -147.93M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Operating Cash Flow | -147.93M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Investing Cash Flow | -72.31M | -71.23M | -192.47M | 0.00 | 0.00 | -40.00M |
| Financing Cash Flow | 262.15M | 203.06M | 186.58M | 42.86M | 169.72M | 89.87M |
ArriVent BioPharma, Inc. Technical Analysis
Positive
31.14
Price Trends
31.58
Negative
30.36
Positive
26.40
Positive
Market Momentum
-0.23
Negative
52.61
Neutral
87.85
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Positive. The current price of 31.14 is above the 20-day moving average (MA) of 30.29, below the 50-day MA of 31.58, and above the 200-day MA of 26.40, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 52.61 is Neutral, neither overbought nor oversold. The STOCH value of 87.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVBP.
ArriVent BioPharma, Inc. Risk Analysis
ArriVent BioPharma, Inc. disclosed 93 risk factors in its most recent earnings report. ArriVent BioPharma, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ArriVent BioPharma, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.96B | -14.10 | -56.19% | ― | -32.27% | -21.09% | |
57 Neutral | $3.53B | -12.27 | -111.96% | ― | 30.24% | -3.25% | |
57 Neutral | $3.66B | -11.80 | -40.51% | ― | 34.52% | 41.20% | |
55 Neutral | $4.26B | -12.37 | -42.27% | ― | 23.86% | 19.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.54B | -8.42 | -50.26% | ― | ― | 8.22% | |
50 Neutral | $1.14B | -2.23 | 1870.38% | ― | -50.80% | 14.80% |
* Healthcare Sector Average
AVBP
ArriVent BioPharma, Inc.
31.00
11.79
61.37%
QURE
uniQure
49.56
33.30
204.80%
IOVA
Iovance Biotherapeutics
8.26
6.03
270.40%
RLAY
Relay Therapeutics
19.42
15.73
426.29%
IVA
Inventiva
4.90
-1.45
-22.83%
TSHA
Taysha Gene Therapies
5.96
3.13
110.60%
ArriVent BioPharma, Inc. Corporate Events
Business Operations and StrategyFinancial Disclosures
ArriVent inks China partnership for ARR-002 development
Positive
Aug 12, 2026
On August 11, 2026, ArriVent BioPharma entered into an exclusive collaboration and license agreement with Shanghai Allist Pharmaceuticals, granting Allist rights to research, develop, manufacture and commercialize ARR-002 in Greater China while re...
Executive/Board ChangesShareholder Meetings
ArriVent BioPharma Stockholders Back Board and Auditor Slate
Positive
Jun 22, 2026
On June 18, 2026, ArriVent BioPharma, Inc. held its 2026 annual meeting of stockholders via live audio webcast, with a quorum of 72.07% of eligible shares represented. Stockholders elected James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.